Tyler Davis was born Nashville, Tennessee. After obtaining his B.S. in biochemistry from Lipscomb University, he entered graduate school at Vanderbilt University to study organic chemistry. There he joined the laboratory of Professor Jeffrey Johnston. During his studies at Vanderbilt, he helped develop novel asymmetric organocatalysts and applied them to the synthesis of chiral nonracemic amines of medicinal importance. Upon completion of his Ph.D., he moved to Fort Collins, Colorado for postdoctoral studies at Colorado State University. There he joined the laboratory of Professor Tomislav Rovis where he studied Rh(III)-catalyzed C-H activation. In 2014, he then moved to Durham, North Carolina, and GSK where he was an investigator in the catalysis and automation group. A year later, Tyler moved on to join the process chemistry group at Merck in Rahway, New Jersey. In his 4+ years at Merck, he spent time in both early-stage (discovery process) and late-stage drug process development. In 2019, Tyler relocated to Indiana to join the process development group at Corteva Agriscience as a process chemist. At Corteva, Tyler has been mainly focused on manufacturing route selection and development.